GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dyadic International Inc (NAS:DYAI) » Definitions » Price-to-Owner-Earnings

DYAI (Dyadic International) Price-to-Owner-Earnings : (As of Mar. 30, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Dyadic International Price-to-Owner-Earnings?

As of today (2025-03-30), Dyadic International's share price is $1.37. Dyadic International does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Dyadic International's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Dyadic International was 1.03. The lowest was 0.78. And the median was 0.93.


DYAI's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 31.73
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-03-30), Dyadic International's share price is $1.37. Dyadic International's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.20. Therefore, Dyadic International's PE Ratio (TTM) for today is At Loss.

As of today (2025-03-30), Dyadic International's share price is $1.37. Dyadic International's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.20. Therefore, Dyadic International's PE Ratio without NRI for today is At Loss.


Dyadic International Price-to-Owner-Earnings Historical Data

The historical data trend for Dyadic International's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dyadic International Price-to-Owner-Earnings Chart

Dyadic International Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Dyadic International Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dyadic International's Price-to-Owner-Earnings

For the Biotechnology subindustry, Dyadic International's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dyadic International's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dyadic International's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Dyadic International's Price-to-Owner-Earnings falls into.


;
;

Dyadic International Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Dyadic International's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.37/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dyadic International  (NAS:DYAI) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Dyadic International Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Dyadic International's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Dyadic International Business Description

Traded in Other Exchanges
N/A
Address
1044 North U.S. Highway One, Suite 201, Jupiter, FL, USA, 33477
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Executives
Ronen Tchelet officer: VP of Research and Bus. Dvlpmt 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Mark A Emalfarb director, 10 percent owner, officer: President, CEO & Chairman C/O DYADIC INTERNATIONAL, INC., 140 INTRACOASTAL POINT DRIVE, SUITE 404, JUPITER FL 33477-5094
Joseph P Hazelton officer: Chief Business Officer 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER FL 33477
Francisco Trust Under Agreement Dated February 28, 1996 10 percent owner C/O ROBERT S. LEVIN, ESQ., TRUSTEE, 180 NORTH LASALLE STREET, SUITE 3200, CHICAGO IL 60601
Patrick K. Lucy director C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Matthew S. Jones officer: Managing Dir of BD & Licensing 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Seth Herbst director 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Barry Buckland director C/O DYADIC INTERNATIONAL, INC., 140 INTERCOASTAL POINTE DR SUITE 404, JUPITER FL 33477
Ping Wang Rawson officer: Chief Financial Officer 140 INTRACOASTAL POINTE DRIVE, SUITE 404, JUPITER X1 33477
Michael P. Tarnok director KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022
Arindam Bose director 4452 BELTWAY DRIVE, ADDISON TX 75001
Jack Kaye director C/O KERYX BIOPHARMACEUTICALS, 750 LEXINGTON AVENUE, NEW YORK X1 10022
Tom Juda 10 percent owner 410 S LUCERNE BLVD, LOS ANGELES CA 90020
John Steven Emerson 10 percent owner 1522 ENSLEY AVENUE, LOS ANGELES CA 90024
Nancy Juda 10 percent owner 410 S LUCERNE BLVD, LOS ANGELES CA 90020